Active Biotech AB Share Price Xetra
Stocks
BTPC
SE0001137985
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - EUR | - |
|
| 07-24 | Active Biotech Doses First Patient in Amended Ho172 Clinical Study of Tasquinimod in Myelofibrosis | CI |
| 07-24 | Active Biotech Doses First Patient in Amended Tasquinimod Myelofibrosis Trial | MT |
| Market Cap | 144M 15.19M 13.14M 12.27M 11.25M 21.17M 1.45B 21.5M 56.49M 724M 57.03M 55.78M 2.39B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 144M 15.19M 13.14M 12.27M 11.25M 21.17M 1.45B 21.5M 56.49M 724M 57.03M 55.78M 2.39B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
81.52% | Yield 2026 * |
-
| Yield 2027 * | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Helén Tuvesson
CEO | Chief Executive Officer | 64 | 30/06/2017 |
Hans Kolam
DFI | Director of Finance/CFO | 75 | 31/12/1999 |
Erik Vahtola
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 06/04/2011 | |
Michael Shalmi
CHM | Chairman | 61 | 22/05/2019 |
Uli Alf Hacksell
BRD | Director/Board Member | 76 | 22/05/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +8.49% | +20.55% | +70.77% | +103.07% | 68.12B | |
| -1.21% | +4.40% | +36.30% | +64.99% | 55.18B | |
| -1.09% | +32.96% | +19.67% | +509.20% | 28.63B | |
| +0.57% | +18.87% | +55.18% | +5.18% | 23.99B | |
| +2.72% | +3.41% | -16.11% | -12.04% | 23.53B | |
| -1.78% | +6.09% | +44.27% | -23.91% | 18.45B | |
| -2.04% | +10.84% | +31.01% | +628.97% | 16.44B | |
| -3.88% | +16.98% | +199.30% | +350.94% | 15.83B | |
| +3.58% | +1.96% | +43.35% | +162.22% | 13.4B | |
| Average | +0.60% | +11.68% | +53.75% | +198.73% | 29.28B | |
| Weighted average by Cap. | +1.81% | +13.10% | +50.82% | +161.83% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -33.2M -3.5M -3.03M -2.83M -2.6M -4.88M -333M -4.96M -13.03M -167M -13.15M -12.87M -552M | 18.2M 1.92M 1.66M 1.55M 1.42M 2.68M 183M 2.72M 7.14M 91.61M 7.21M 7.05M 303M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- ACTI Stock
- BTPC Stock
Select your edition
All financial news and data tailored to specific country editions
